低危重度主动脉瓣狭窄患者随机试验外的主动脉瓣置换
该单中心研究纳入2000至2019年接受SAVR的6772例重度主动脉瓣狭窄患者,其中5310例(78.4%)为低外科风险,40.8%存在TAVR与SAVR随机试验排除的至少一项主要标准。30天死亡率和卒中率分别为1.9%和2.4%,CMTV组死亡率较高。
要点
- 低危重度主动脉瓣狭窄患者中约四成存在随机试验排除的解剖或临床特征。
- 低危SAS患者SAVR后30天死亡率为1.9%,卒中率为2.4%。
- 需同期二尖瓣/三尖瓣干预者30天死亡率较高(5.9%)。
核心结论
- 近半数接受SAVR的低危重度主动脉瓣狭窄患者存在TAVR与SAVR随机试验未评估的主要标准。
- 除需同期二尖瓣/三尖瓣干预者外,各组临床结局优于或类似于外科评分预测。
研究设计与样本
- 单中心研究纳入2000至2019年连续接受SAVR的重度主动脉瓣狭窄患者。
- 低外科风险定义为Society of Thoracic Surgeons评分<4%。
- 最终分析低危患者5310例,平均STS评分为1.94±0.87%。
主要发现
- 低危患者中40.8%存在至少一项以下特征:非三叶式主动脉瓣(27.6%)、严重冠状动脉疾病(5.8%)、需同期二尖瓣/三尖瓣干预(5.8%)、需同期升主动脉替换(10.5%)。
- 整体低危队列30天死亡率为1.9%,卒中率为2.4%。
- 严重冠状动脉疾病组30天死亡率为2.6%(OR 1.79;95%CI 0.85-3.75),需同期升主动脉替换组为2.1%(OR 1.64;95%CI 0.88-3.05),与非上述组相比无显著差异。
- 非三叶式主动脉瓣组30天死亡率为0.9%(OR 0.42;95%CI 0.22-0.81),低于其余队列。
- 需同期二尖瓣/三尖瓣干预组30天死亡率为5.9%(OR 2.61;95%CI 1.51-4.5),高于其余队列。
临床怎么用
- 对于低危重度主动脉瓣狭窄患者,应评估是否存在随机试验排除的解剖或临床特征。
- 需同期二尖瓣/三尖瓣干预的患者SAVR术后30天死亡率较高,临床决策需谨慎。
局限性
- 单中心回顾性研究,结果外推需谨慎。
- 仅纳入接受SAVR的患者,未直接比较TAVR。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent randomized trials including low-risk patients showed positive results for transcatheter aortic valve replacement (TAVR) compared to surgical aortic valve replacement (SAVR), but patients with non-tricuspid aortic valve (NTAV), severe coronary artery disease (SevCAD), and those requiring concomitant mitral/tricuspid valve (CMTV) or concomitant ascending aorta replacement (CAAR) interventions were excluded. OBJECTIVES: This study sought to evaluate the presence and impact of the main clinical variables not evaluated in TAVR versus SAVR trials (NTAV, SevCAD, and CMTV or CAAR intervention) in a large series of consecutive low-risk patients with severe aortic stenosis (SAS) undergoing SAVR. METHODS: Single-center study including consecutive patients with SAS and low surgical risk (Society of Thoracic Surgeons score of <4%) undergoing SAVR. Baseline, procedural characteristics, and 30-day outcomes were prospectively collected. RESULTS: Of 6,772 patients with SAS who underwent SAVR between 2000 and 2019, 5,310 (78.4%) exhibited a low surgical risk (mean Society of Thoracic Surgeons score: 1.94 ± 0.87%). Of these, 2,165 patients (40.8%) had at least 1 of the following: NTAV (n = 1,468, 27.6%), SevCAD (n = 307, 5.8%), CMTV (n = 306, 5.8%), and CAAR (n = 560, 10.5%). The 30-day mortality and stroke rates for the overall low-risk SAS cohort were 1.9% and 2.4%, respectively. The mortality rate was similar in the SevCAD (2.6%) and CAAR (2.1%) groups versus the rest of the cohort (odds ratio [OR]: 1.79; 95% confidence interval [CI]: 0.85 to 3.75, and OR: 1.64; 95% CI: 0.88 to 3.05, respectively), lower in the NTAV group (0.9%; OR: 0.42; 95% CI: 0.22 to 0.81), and higher in the CMTV group (5.9%; OR: 2.61; 95% CI: 1.51 to 4.5). CONCLUSIONS: In a real-world setting, close to one-half of the low-risk patients with SAS undergoing SAVR exhibited at least 1 major criterion not evaluated in TAVR versus SAVR randomized trials. Clinical outcomes were better than or similar to those predicted by surgical scores in all groups but those patients requiring CMTV intervention. These results may help determine the impact of implementing the results of TAVR-SAVR trials in real practice and may inform future trials in specific groups.
引用
- Alperi A, Voisine P, Kalavrouziotis D, et al. Aortic Valve Replacement in Low-Risk Patients With Severe Aortic Stenosis Outside Randomized Trials. J Am Coll Cardiol. 2021. PMID: 33446305. doi:10.1016/j.jacc.2020.10.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。